Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVBP NASDAQ:DERM NASDAQ:FBIO NASDAQ:MNMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$18.02+6.3%$21.58$15.47▼$36.37$687.64M1.17281,266 shs543,062 shsDERMJourney Medical$7.25-15.1%$7.16$3.54▼$8.90$198.95M0.8148,083 shs484,841 shsFBIOFortress Biotech$1.93-4.0%$1.90$1.33▼$2.36$59.44M1.76173,085 shs236,916 shsMNMDMind Medicine (MindMed)$9.97-1.8%$8.22$4.70▼$10.49$772.29M2.491.32 million shs1.04 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma-2.70%-12.85%-21.64%-9.60%-24.33%DERMJourney Medical+8.51%+18.45%+19.44%+43.05%+101.42%FBIOFortress Biotech+4.69%+5.51%+6.35%+21.08%+13.56%MNMDMind Medicine (MindMed)+1.50%+5.29%+25.93%+55.20%+48.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVBPArriVent BioPharma1.9074 of 5 stars4.60.00.00.01.70.80.0DERMJourney Medical1.6537 of 5 stars3.51.00.00.01.60.80.6FBIOFortress Biotech2.6176 of 5 stars3.51.00.00.02.43.30.6MNMDMind Medicine (MindMed)2.0903 of 5 stars3.61.00.00.02.80.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVBPArriVent BioPharma 3.14Buy$39.14117.22% UpsideDERMJourney Medical 3.00Buy$10.8349.43% UpsideFBIOFortress Biotech 3.00Buy$21.00988.08% UpsideMNMDMind Medicine (MindMed) 3.22Buy$24.71147.89% UpsideCurrent Analyst Ratings BreakdownLatest DERM, FBIO, AVBP, and MNMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025DERMJourney MedicalLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $13.008/12/2025AVBPArriVent BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $42.008/12/2025AVBPArriVent BioPharmaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $33.008/4/2025MNMDMind Medicine (MindMed)OppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$25.008/1/2025MNMDMind Medicine (MindMed)Chardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.007/22/2025AVBPArriVent BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.007/10/2025AVBPArriVent BioPharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$33.006/24/2025AVBPArriVent BioPharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$39.00 ➝ $44.006/24/2025AVBPArriVent BioPharmaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.005/20/2025AVBPArriVent BioPharmaJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.005/15/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVBPArriVent BioPharmaN/AN/AN/AN/A$6.16 per shareN/ADERMJourney Medical$56.13M3.01N/AN/A$0.91 per share7.97FBIOFortress Biotech$57.67M0.99N/AN/A($0.06) per share-32.17MNMDMind Medicine (MindMed)N/AN/AN/AN/A$2.44 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVBPArriVent BioPharma-$80.49M-$3.77N/AN/AN/AN/A-55.40%-51.97%8/13/2025 (Estimated)DERMJourney Medical-$14.67M-$0.39N/AN/AN/A-15.49%-49.90%-11.44%N/AFBIOFortress Biotech-$46M-$2.23N/AN/AN/A-71.24%-4,712.53%-27.67%N/AMNMDMind Medicine (MindMed)-$108.68M-$1.53N/AN/AN/AN/A-50.24%-39.41%N/ALatest DERM, FBIO, AVBP, and MNMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025DERMJourney Medical-$0.07-$0.16-$0.09-$0.16$14.93 million$15.01 million8/11/2025Q2 2025AVBPArriVent BioPharma-$0.70-$0.90-$0.20-$0.90N/AN/A7/31/2025Q2 2025MNMDMind Medicine (MindMed)-$0.38-$0.50-$0.12-$0.50N/AN/A5/14/2025Q1 2025DERMJourney Medical-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVBPArriVent BioPharmaN/AN/AN/AN/AN/ADERMJourney MedicalN/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVBPArriVent BioPharmaN/A12.7414.34DERMJourney Medical1.071.341.03FBIOFortress Biotech1.741.721.55MNMDMind Medicine (MindMed)0.224.984.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVBPArriVent BioPharma9.48%DERMJourney Medical7.25%FBIOFortress Biotech96.51%MNMDMind Medicine (MindMed)27.91%Insider OwnershipCompanyInsider OwnershipAVBPArriVent BioPharma18.58%DERMJourney Medical15.03%FBIOFortress Biotech27.90%MNMDMind Medicine (MindMed)2.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVBPArriVent BioPharma4040.57 million27.86 millionN/ADERMJourney Medical9023.30 million19.80 millionN/AFBIOFortress Biotech17029.57 million21.32 millionOptionableMNMDMind Medicine (MindMed)4076.09 million74.22 millionOptionableDERM, FBIO, AVBP, and MNMD HeadlinesRecent News About These CompaniesMind Medicine (MindMed) (NASDAQ:MNMD) Hits New 52-Week High - Here's What HappenedAugust 13 at 2:38 PM | marketbeat.comIf You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have TodayAugust 12 at 5:00 AM | fool.comCould This Psychedelic Drug Stock Be a Top Buy for 2026?August 8, 2025 | msn.comCould This Psychedelic Drug Stock Be a Top Buy for 2026?August 8, 2025 | msn.comResearch Analysts Issue Forecasts for MNMD Q3 EarningsAugust 8, 2025 | americanbankingnews.comHC Wainwright Has Negative Outlook for MNMD Q3 EarningsAugust 7, 2025 | marketbeat.comRoth Capital Brokers Reduce Earnings Estimates for MNMDAugust 7, 2025 | marketbeat.com1 Reason to Buy MindMed (MNMD)August 7, 2025 | fool.comHC Wainwright Has Positive Estimate for MNMD FY2028 EarningsAugust 7, 2025 | americanbankingnews.comMind Medicine (MindMed) (NASDAQ:MNMD) Research Coverage Started at OppenheimerAugust 7, 2025 | americanbankingnews.comRoth Capital Issues Pessimistic Forecast for MNMD EarningsAugust 7, 2025 | americanbankingnews.comFY2028 Earnings Estimate for MNMD Issued By HC WainwrightAugust 6, 2025 | marketbeat.comIs Mind Medicine stock a buy?August 6, 2025 | cantechletter.comCMind Medicine (MindMed) (NASDAQ:MNMD) Shares Up 10.9% - Time to Buy?August 5, 2025 | marketbeat.comMind Medicine (MindMed) (NASDAQ:MNMD) Now Covered by OppenheimerAugust 5, 2025 | marketbeat.comMind Medicine (MindMed) (NASDAQ:MNMD) Issues Earnings ResultsAugust 3, 2025 | marketbeat.comMind Medicine (MindMed) (NASDAQ:MNMD) Given Buy Rating at Chardan CapitalAugust 2, 2025 | marketbeat.comMindMed (MNMD) Q2 Net Loss Jumps 625%August 1, 2025 | fool.comMind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call TranscriptJuly 31, 2025 | seekingalpha.comMindMed Reports Q2 2025 Financial Results and Business UpdatesJuly 31, 2025 | businesswire.comMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Average Recommendation of "Buy" by AnalystsJuly 29, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDERM, FBIO, AVBP, and MNMD Company DescriptionsArriVent BioPharma NASDAQ:AVBP$18.02 +1.07 (+6.31%) Closing price 04:00 PM EasternExtended Trading$18.00 -0.02 (-0.11%) As of 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Journey Medical NASDAQ:DERM$7.25 -1.29 (-15.11%) Closing price 04:00 PM EasternExtended Trading$7.80 +0.56 (+7.66%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Fortress Biotech NASDAQ:FBIO$1.93 -0.08 (-3.98%) Closing price 04:00 PM EasternExtended Trading$1.96 +0.03 (+1.55%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Mind Medicine (MindMed) NASDAQ:MNMD$9.97 -0.18 (-1.77%) Closing price 04:00 PM EasternExtended Trading$9.99 +0.02 (+0.24%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CAVA’s Honeymoon Ends With a 16% Stock Drop Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests 5 Stocks Insiders Are Selling That Analysts Say Buy CoreWeave Pulls Back Into a Screaming Buy Amazon’s Bears Have Raised the White Flag—Get Excited Rocket Lab Scores Analyst Upgrades, Finalizes Geost Takeover Why BigBear.ai Stock's Dip on Earnings Can Be an Opportunity Catalysts Align: Archer Beats Estimates, Delivers Aircraft to UAE Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.